Share

Related Links

  • BRIC: Background
  • Elsevier Ltd is not responsible for the content of external websites.

Related Stories

  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Government UK life sciences strategy a significant step forward
    The BioIndustry Association (BIA) welcomes the Prime Minister's announcement of a coordinated life sciences strategy which could provide a foundation for the future of the bioscience sector in the UK
  • Together we will beat cancer
    Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer.
  • Drug discovery in the next decade:innovation needed ASAP
    The pharmaceutical sector, a cornerstone of the healthcare industry, is undergoing dramaticchange, primarily caused by reduced output of new medicines from research and development(R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overallcurrent economic downturn. This makes demands of all pharmaceutical companies to find better ways to increase their output of new drugs, through innovation, to both treat patients and meet their shareholders’ expectations.
    Members' Content
  • Lack of alignment threatens drug discovery process
    With looming patient cliffs, drying pipelines and the need for open collaboration, now more than ever the pharma sector needs a co-ordinated approach to get back on track, says a leading industry player.

Top 5 Stories

News

Private sector urged to seize opportunity and back Research Council commitment to bioprocessing R&D

26 November 2009

Private industry has been urged to join a public sector commitment to fund advanced manufacturing research and development in bioprocessing.

£9 million of funding has been committed by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC) to collaborative research with industry in bioprocessing, the sector that develops the technology, techniques and processes to manufacture new medicines from biological materials.

Bioprocessing is expected to underpin half of the top 100 medicines, as measured by sales, by 2014. As an advanced manufacturing sector, it is one of the ‘value added’, knowledge-based industries that are expected to contribute to future UK economic growth, as well as helping to deliver new and effective medicines more quickly to the clinic.

The two Research Councils have committed the funding to the second phase of a BBSRC-led public–private partnership, the Bioprocessing Research Industry Club: BRIC 2. The partnership gives industry a voice in setting the strategic direction of research to ensure that outcomes from the science funded are relevant to the sector and, therefore, able to benefit the UK economy quickly.

Dr Celia Caulcott, BBSRC Director for Innovation and Skills, said: ‘We have been running the first phase of the partnership since 2005, when we committed to investing a combined total of £14M. I am proud to say we have 17 bioprocessing companies in the Club. BRIC 2 will build on early successes, but needs the commitment of both the existing and new companies in the sector.’

The first phase of BRIC has established a bioprocessing community in the UK. Twenty-five research projects have pushed forward knowledge in bioprocessing; more than 40% of the research leaders have reported new products, processes or tools and technologies arising from their projects. One important output from bioprocessing is an increase in the efficiency of the production of large molecules for biopharmaceuticals.

Dr Caulcott said: ‘BRIC research projects benefit the overall bioprocessing sector through reducing product development costs, improving the predictability of processes and helping companies to meet regulations. In addition, the member companies who contribute a relatively small amount to the research Club funding pot receive early access to these findings.’

BRIC is managed by BBSRC with support from bioProcessUK, part of the TSB-funded HealthTech and Medicines Knowledge Transfer Network. The first phase of BRIC was launched in 2005 to deliver research and training relevant to industrial bioprocessing.

 

This article is featured in:
Companies and People

 

Comment on this article

You must be registered and logged in to leave a comment about this article.